- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
UK's Cancer Drugs Fund Will Improve Access But Evaluate Value
While the 40% funding boost will help patients continue current expensive treatment, or improve access for others, determining "value for money" is high on the NHS agenda.
Pioneering cancer drugs will not be made available under a flagship scheme founded by David Cameron if they do not represent good value for money.
Jeremy Hunt, the Health Secretary, will on Thursday boost funding for the flagship Cancer Drugs Fund by 40 per cent to almost £300 million a year.
The move will give thousands more cancer patients access to cutting-edge cancer drugs which would otherwise be deemed too expensive for the NHS.
Under new plans clinicians will examine whether the drugs on offer are the most effective available to ensure "this extensive additional funding is spent in the best way for patients".
No patients will have any current treatments terminated, and patients with rare conditions who have no other option will continue to get access to the most effective drugs. Officials believe that the move will give the NHS more bargaining power and help reduce the prices of drugs.
Read the complete report: http://bit.ly/1qmVcl0
Source: The Telegraph
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
